At a glance
ClinicalIndex Comparison RecordN/ACompleted· 58 enrolled
Drug / intervention
16-contact Directional Deep Brain Stimulationdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study to Evaluate Boston Scientific Vercise Cartesia 16-contact Directional Lead (X/HX) With Deep Brain Stimulation (DBS) Systems for the Treatment of Parkinson's Disease (PD)
In Brief
A clinical study evaluating 16-contact Directional Deep Brain Stimulation for Parkinson Disease. Completed, enrolled 58 participants across 10 sites in 3 countries.
Detailed Summary
The purpose of the study is to document patient outcomes including effectiveness for Boston Scientific Corporation's Vercise Cartesia 16-contact Directional Lead(s) (X/HX) with Deep Brain Stimulation (DBS) systems for the treatment of Parkinson's Disease (PD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesGermany, Netherlands, United Kingdom
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartNov 2020
Primary CompletionFeb 2023
Study CompletionJan 2025
TodayJul 2026
First PostedOct 8, 2020
Enrollment StartNov 2, 2020
Primary CompletionFeb 27, 2023
Study CompletionJan 28, 2025
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 5.7 years ago
Interventions
16-contact Directional Deep Brain Stimulationdevice
Deep Brain Stimulation with 16-contact Directional Lead